SynAct Pharma has received useful external validation for lead asset resomelagon’s dengue programme, with a World Health Organization (WHO)-led review published in The Lancet Microbe identifying it as one of only six candidates with sufficient efficacy evidence to support further clinical development. Notably, resomelagon is the only host-directed therapy among the six. This is relevant given the substantial unmet need: there are currently no approved dengue-specific treatments, with clinical management largely limited to supportive care. The WHO estimates 100–400m dengue infections annually, while reported cases reached a record 14m+ in 2024. Brazil is a particularly important market given its high disease burden.
LÄS MER
